PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 5, 2025Sci23 citationsOpen Access

A Review of Artificial Intelligence (AI)-Driven Smart and Sustainable Drug Delivery Systems: A Dual-Framework Roadmap for the Next Pharmaceutical Paradigm

View Full Paper
JSJirapornchai Suksaeree

Key Points

  • AI enhances personalization in drug delivery systems and promotes sustainability through advanced technologies.
  • Bayesian optimization and machine learning enable predictions of critical quality attributes in polymeric systems.
  • This review integrates AI strategies for drug delivery with a structured life-cycle perspective and regulatory frameworks.
  • Addressing limitations requires ethical considerations and established regulatory frameworks for AI applications in pharmaceutics.

Abstract

Artificial intelligence (AI) is transforming pharmaceutical science by shifting drug delivery research from empirical experimentation toward predictive, data-driven innovation. This review critically examines the integration of AI across formulation design, smart drug delivery systems (DDSs), and sustainable pharmaceutics, emphasizing its role in accelerating development, enhancing personalization, and promoting environmental responsibility. AI techniques—including machine learning, deep learning, Bayesian optimization, reinforcement learning, and digital twins—enable precise prediction of critical quality attributes, generative discovery of excipients, and closed-loop optimization with minimal experimental input. These tools have demonstrated particular value in polymeric and nano-based systems through their ability to model complex behaviors and to design stimuli-responsive DDS capable of real-time therapeutic adaptation. Furthermore, AI facilitates the transition toward green pharmaceutics by supporting biodegradable material selection, energy-efficient process design, and life-cycle optimization, thereby aligning drug delivery strategies with global sustainability goals. However, challenges persist, including limited data availability, lack of model interpretability, regulatory uncertainty, and the high computational cost of AI systems. Addressing these limitations requires the implementation of FAIR data principles, physics-informed modeling, and ethically grounded regulatory frameworks. Overall, AI serves not as a replacement for human expertise but as a transformative enabler, redefining DDS as intelligent, adaptive, and sustainable platforms for future pharmaceutical development. Compared with previous reviews that have considered AI-based formulation design, smart DDS, and green pharmaceutics separately, this article integrates these strands and proposes a dual-framework roadmap that situates current AI-enabled DDS within a structured life-cycle perspective and highlights key translational gaps.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jirapornchai Suksaeree (2025) studied this question.

synapsesocial.com/papers/6932313d8e51979591dcef52https://doi.org/10.3390/sci7040179
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Transparency and accountability in AI systems: safeguarding wellbeing in the age of algorithmic decision-making2024 · 394 citations
  2. 2Digital twin for personalized medicine development2025 · 62 citations
  3. 3Digital Twin Implementation in the Pharmaceutical Industry2024 · 2 citations
  4. 4PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation2018 · 43,512 citations
  5. 5Can We Create a Circular Pharmaceutical Supply Chain (CPSC) to Reduce Medicines Waste?2020 · 103 citations